This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wootton, M.
Right arrow Articles by Howe, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wootton, M.
Right arrow Articles by Howe, R. A.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, February 2007, p. 329-332, Vol. 45, No. 2
0095-1137/07/$08.00+0     doi:10.1128/JCM.01508-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

A Multicenter Study Evaluating the Current Strategies for Isolating Staphylococcus aureus Strains with Reduced Susceptibility to Glycopeptides{triangledown}

Mandy Wootton,1* Alasdair P. MacGowan,2 Timothy R. Walsh,3 and Robin A. Howe1

Specialist Antimicrobial Chemotherapy Unit, NPHS Microbiology Cardiff, University Hospital Wales, Heath Park, Cardiff CF14 4XW, United Kingdom,1 Bristol Centre for Antimicrobial Research and Evaluation (BCARE), Medical Microbiology, Southmead Hospital, North Bristol Healthcare Trust, Bristol BS10 5NB, United Kingdom,2 Department of Medical Microbiology, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, United Kingdom3

Received 21 July 2006/ Returned for modification 5 October 2006/ Accepted 6 November 2006

Glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA (hGISA) strains are notoriously difficult to detect in the diagnostic laboratory. The clinical importance of GISA, and particularly hGISA, will only be obvious when a definitive detection method is available. A few novel GISA and hGISA detection methods have been proposed; however, their validity has never been tested on a significant scale and in different laboratories. This study compares three screening methods for detecting GISA and hGISA strains in 12 laboratories, using a blind panel of 48 strains with known glycopeptide susceptibilities. The three screening methods used were brain heart infusion agar with 6 mg/liter vancomycin (BHIA6V) (CDC/CLSI), Mueller-Hinton agar with 5 mg/liter teicoplanin (MHA5T) (European Antimicrobial Resistance Surveillance System [EARSS]), and the macrodilution method Etest (MET) (EARSS), with population analysis profile-area under the curve analysis as the gold standard. Sensitivity and specificity were highest for MHA5T and MET, which identified 82.5% and 85.9% of strains, respectively. BHIA6V had poor sensitivity, particularly for hGISA (11.5% of strains were detected), and gave the largest interlaboratory variation in performance. MET exhibited the least interlaboratory variation. It is essential that laboratories use appropriate methods to detect GISA/hGISA strains so that the prevalence and clinical importance of these strains can be assessed properly.

* Corresponding author. Mailing address: BCARE, Department of Cellular and Molecular Medicine, Medical Sciences, University of Bristol, Bristol BS8 1TD, United Kingdom. Phone: 44 117 3317658. Fax: 44 117 9287896. E-mail: mandy.wootton{at}bristol.ac.uk.

{triangledown} Published ahead of print on 15 November 2006.

Journal of Clinical Microbiology, February 2007, p. 329-332, Vol. 45, No. 2
0095-1137/07/$08.00+0     doi:10.1128/JCM.01508-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Sader, H. S., Jones, R. N., Rossi, K. L., Rybak, M. J. (2009). Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals. J Antimicrob Chemother 64: 1024-1028 [Abstract] [Full Text]  
  • Sun, W., Chen, H., Liu, Y., Zhao, C., Nichols, W. W., Chen, M., Zhang, J., Ma, Y., Wang, H. (2009). Prevalence and Characterization of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates from 14 Cities in China. Antimicrob. Agents Chemother. 53: 3642-3649 [Abstract] [Full Text]  
  • Swenson, J. M., Anderson, K. F., Lonsway, D. R., Thompson, A., McAllister, S. K., Limbago, B. M., Carey, R. B., Tenover, F. C., Patel, J. B. (2009). Accuracy of Commercial and Reference Susceptibility Testing Methods for Detecting Vancomycin-Intermediate Staphylococcus aureus. J. Clin. Microbiol. 47: 2013-2017 [Abstract] [Full Text]  
  • Musta, A. C., Riederer, K., Shemes, S., Chase, P., Jose, J., Johnson, L. B., Khatib, R. (2009). Vancomycin MIC plus Heteroresistance and Outcome of Methicillin-Resistant Staphylococcus aureus Bacteremia: Trends over 11 Years. J. Clin. Microbiol. 47: 1640-1644 [Abstract] [Full Text]  
  • Leonard, S. N., Rossi, K. L., Newton, K. L., Rybak, M. J. (2009). Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrob Chemother 63: 489-492 [Abstract] [Full Text]  
  • Rose, W. E., Leonard, S. N., Rossi, K. L., Kaatz, G. W., Rybak, M. J. (2009). Impact of Inoculum Size and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA) on Vancomycin Activity and Emergence of VISA in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 53: 805-807 [Abstract] [Full Text]  
  • Leonard, S. N., Rybak, M. J. (2009). Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. J Antimicrob Chemother 63: 155-160 [Abstract] [Full Text]  
  • Kosowska-Shick, K., Ednie, L. M., McGhee, P., Smith, K., Todd, C. D., Wehler, A., Appelbaum, P. C. (2008). Incidence and Characteristics of Vancomycin Nonsusceptible Strains of Methicillin-Resistant Staphylococcus aureus at Hershey Medical Center. Antimicrob. Agents Chemother. 52: 4510-4513 [Abstract] [Full Text]  
  • Lalani, T., Federspiel, J. J., Boucher, H. W., Rude, T. H., Bae, I.-G., Rybak, M. J., Tonthat, G. T., Corey, G. R., Stryjewski, M. E., Sakoulas, G., Chu, V. H., Alder, J., Steenbergen, J. N., Luperchio, S. A., Campion, M., Woods, C. W., Fowler, V. G. (2008). Associations between the Genotypes of Staphylococcus aureus Bloodstream Isolates and Clinical Characteristics and Outcomes of Bacteremic Patients. J. Clin. Microbiol. 46: 2890-2896 [Abstract] [Full Text]  
  • D'mello, D., Daley, A. J., Rahman, M. S., Qu, Y., Garland, S., Pearce, C., Deighton, M. A. (2008). Vancomycin Heteroresistance in Bloodstream Isolates of Staphylococcus capitis. J. Clin. Microbiol. 46: 3124-3126 [Abstract] [Full Text]  
  • Rybak, M. J., Leonard, S. N., Rossi, K. L., Cheung, C. M., Sadar, H. S., Jones, R. N. (2008). Characterization of Vancomycin-Heteroresistant Staphylococcus aureus from the Metropolitan Area of Detroit, Michigan, over a 22-Year Period (1986 to 2007). J. Clin. Microbiol. 46: 2950-2954 [Abstract] [Full Text]  
  • Chua, T., Moore, C. L., Perri, M. B., Donabedian, S. M., Masch, W., Vager, D., Davis, S. L., Lulek, K., Zimnicki, B., Zervos, M. J. (2008). Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus Bloodstream Isolates in Urban Detroit. J. Clin. Microbiol. 46: 2345-2352 [Abstract] [Full Text]  
  • Rose, W. E., Leonard, S. N., Rossi, K. L., Kaatz, G. W., Rybak, M. J. (2008). Relationships between vancomycin pharmacodynamics and the emergence of vancomycin-intermediate Staphylococcus aureus (VISA) from heterogeneous VISA in an in vitro pharmacodynamic model. J Antimicrob Chemother 0: dkn037v1-6 [Abstract] [Full Text]  
  • Holmes, R. L., Jorgensen, J. H. (2008). Inhibitory Activities of 11 Antimicrobial Agents and Bactericidal Activities of Vancomycin and Daptomycin against Invasive Methicillin-Resistant Staphylococcus aureus Isolates Obtained from 1999 through 2006. Antimicrob. Agents Chemother. 52: 757-760 [Abstract] [Full Text]  
  • Amiali, N. M., Mulvey, M. R., Berger-Bachi, B., Sedman, J., Simor, A. E., Ismail, A. A. (2008). Evaluation of Fourier transform infrared spectroscopy for the rapid identification of glycopeptide-intermediate Staphylococcus aureus. J Antimicrob Chemother 61: 95-102 [Abstract] [Full Text]  
  • Fitzgibbon, M. M., Rossney, A. S., O'Connell, B. (2007). Investigation of Reduced Susceptibility to Glycopeptides among Methicillin-Resistant Staphylococcus aureus Isolates from Patients in Ireland and Evaluation of Agar Screening Methods for Detection of Heterogeneously Glycopeptide-Intermediate S. aureus. J. Clin. Microbiol. 45: 3263-3269 [Abstract] [Full Text]  
  • Julian, K., Kosowska-Shick, K., Whitener, C., Roos, M., Labischinski, H., Rubio, A., Parent, L., Ednie, L., Koeth, L., Bogdanovich, T., Appelbaum, P. C. (2007). Characterization of a Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus Strain in a Patient with Endocarditis. Antimicrob. Agents Chemother. 51: 3445-3448 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»